Onycholysis associated with capecitabine in patients with breast cancer

Journal of Cutaneous Medicine and Surgery

Volumn 12, Issue 2, 2008, Pages 93-95

  Hogeling, Marcia ^a,b,c   Howard, Jessica ^a,b   Kanigsberg, Nordau ^a,b   Finkelstein, Harvey ^a,b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CEFALEXIN; CICLOPIROX; CLOBETASOL PROPIONATE; DOCETAXEL; GEMCITABINE; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE; FLUOROURACIL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BACTERIUM CULTURE; BREAST CANCER; CANCER CHEMOTHERAPY; CASE REPORT; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERKERATOSIS; ONYCHOLYSIS; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; KERATINOCYTE; MIDDLE AGED; NAIL; PATHOLOGY; REVIEW;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; BREAST NEOPLASMS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; KERATINOCYTES; MIDDLE AGED; NAILS; ONYCHOLYSIS;

EID: 47549113298     PISSN: 12034754     EISSN: None     Source Type: Journal    
DOI: 10.2310/7750.2008.07028     Document Type: Article

References (15)

1. Bolognia JL, Jorizzo JL, Rapini RP, et al. Dermatology. Philadelphia: Mosby; 2003.
2. Jackson RJ. Morphological diagnosis of skin disease. Grimsby, ON: Manticore; 1998.
3. Chen GY, Chen YH, Hsu MM, et al. Onychomadesis and onycholysis associated with capecitabine. Br J Dermatol 2001; 145:521-2.
4. Uhlmann C, Ballabeni P, Rijken N, et al. Capecitabine with weekly paclitaxel for advanced breast cancer: a phase 1 dose-finding trial. Oncology 2004;67:117-22.
5. Ishikawa T, Utoh M, Sawada N, et al. Tumour selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. Biochem Pharmacol 1998;55:1091-7.
6. Walko CM, Lindley C. Capecitabine: a review. Clin Ther 2005;27: 23-44.
7. Scheithauer W, Blum J. Coming to grips with hand-foot syndrome. Insights from clinical trials evaluating capecitabine. Oncology 2004;18:1161-8.
8. Fischel JL, Formento P, Ciccolini J, et al. Lack of contribution of dihydrofluorouracil and alpha-fluoro-beta-alanine to the cytotoxicity of 5′-deoxy-5-fluorouridine on human keratinocytes. Anticancer Drugs 2004;15:969-74.
9. Hussian S, Anderson DN, Salvati ME, et al. Onycholysis as a complication of systemic chemotherapy. Cancer 2000;88:2367-71.
10. Maino KL, Norwood C, Stashower ME. Onycholysis with the appearance of a "sunset" secondary to capecitabine. Cutis 2003;72: 234-6.
11. Munoz A, Barcelo R, Rubio I, et al. Onycholysis associated with capecitabine in combination with irinotecan in two patients with colorectal cancer. J Natl Cancer Inst 2003;95:1252-3.
12. Creamer JD, Mortimer PS, Powles TJ. Mitozantrone-induced onycholysis, a series of five cases. Clin Exp Dermatol 1995;20:459-61.
13. Daniel CR III, Scher RK. Nail changes caused by systemic drugs or ingestants. Dermatol Clin 1985;3:491-5.
14. Baran R, Juhlin I. Drug-induced photo-onycholysis. J Am Acad Dermatol 1987;17:1012-6.
15. Picardo M, Tosti A, Marchese C, et al. Characterization of cultured nail matrix cells. J Am Acad Dermatol 1994;30:434-40.